Charles Schwab Investment Management Inc Amylyx Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 435,903 shares of AMLX stock, worth $828,215. This represents 0.0% of its overall portfolio holdings.
Number of Shares
435,903
Previous 387,620
12.46%
Holding current value
$828,215
Previous $5.71 Million
78.32%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding AMLX
# of Institutions
184Shares Held
50.3MCall Options Held
5.84MPut Options Held
2.06M-
Vanguard Group Inc Valley Forge, PA5.35MShares$10.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$8.5 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.94MShares$5.59 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.47MShares$4.7 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$3.93 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $111M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...